Rash
8
0
0
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
37.5%
3 terminated out of 8 trials
57.1%
-29.4% vs benchmark
0%
0 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
Implementation of a Minor Ailment Service in Community Pharmacy Practice
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age
Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX
Sorafenib-induced Hand- Foot Skin Reaction Treatment
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash